A meta‐analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

Calvet, Xavier; García, Neus; Lopez, Thais Torralbo; Gisbert, Javier P.; Gené, Emili; Roque, Matheus

doi:10.1046/j.1365-2036.2000.00744.x

Cited by 224 publications

(152 citation statements)

References 29 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Most of the recommendations by the consensus groups recommend a period of 7 days, especially because of the cost factor. In reality, meta-analysis studies have shown a 4% gain by extending to 10 days and 5% with 14 days (15,60,64,91) . For patients with a possible or proven history of penicillin allergy to the scheme described above is recommended replacing amoxicillin with the furazolidone 200 mg twice a day (31,35) .…”

Section: Statement 27mentioning

confidence: 99%

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho

Maguinilk

Zaterka³

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

Significant progress has been obtained since the Second Brazilian Consensus Conference on Helicobacter pylori Infection held in 2004, in São Paulo, SP, Brazil, and justify a third meeting to establish updated guidelines on the current management of H. pylori infection. The Third Brazilian Consensus Conference on H pylori Infection was organized by the Brazilian Nucleus for the Study of Helicobacter, a Department of the Brazilian Federation of Gastroenterology and took place on April 12-15, 2011, in Bento Gonçalves, RS, Brazil. Thirty-one delegates coming from the five Brazilian regions and one international guest, including gastroenterologists, pathologists, epidemiologists, and pediatricians undertook the meeting. The participants were allocated in one of the five main topics of the meeting: H pylori, functional dyspepsia and diagnosis; H pylori and gastric cancer; H pylori and other associated disorders; H pylori treatment and retreatment; and, epidemiology of H pylori infection in Brazil. The results of each subgroup were submitted to a final consensus voting to all participants. Relevant data were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. Seventy per cent and more votes were considered as acceptance for the final statement. This article presents the main recommendations and conclusions to guide Brazilian doctors involved in the management of H pylori infection.

show abstract

Section: Statement 27mentioning

confidence: 99%

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Coelho

Maguinilk

Zaterka³

et al. 2013

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The first method suggested that increasing the STT duration would improve treatment efficacy. In an early meta-analysis, a 14-d STT regimen raised the eradication rate compared to a 7-d regimen [71] . Another meta-analysis supported this result by showing that extending STT over 7 d improved the eradication rate [72] .…”

Section: Publication Treatment Duration Patients Therapy Regimen Eradmentioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori ) has been associated with gastroduodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Core tip: This article reviews the recent literature describing antibiotic resistance and trends in Helicobacter pylori (H. pylori ) treatment. As there is no effective conventional therapy, new treatments are being developed and bismuth quadruple, sequential, concomitant therapies are recommended as a first-line regimen in regions with high levels of clarithromycin resistance. Quinolones have also been used for H. pylori treatment, although the cure rate has gradually reduced with this approach. New therapeutic directions include probiotic supplementation, tailored therapy, novel agents, and nanotechnology.

show abstract

“…Antacids (aluminium hydroxide and magnesium trisilicate combination) are also used to decrease the gastric acid secretion (Rang et al, 2003). The drugs used for the treatment of H. pylori associated gastric and duodenal ulcers-triple therapy regimen, which includes a proton pump inhibitor (omeprazole, lansoprazole), antibiotics (clarithromycin and metronidazole) (Rakesh et al, 2010: Calvet et al, 2000: Enaganti, 2006.…”

Section: Treatment Strategiesmentioning

confidence: 99%

Medicinal plants with gastroprotective potential

Majeed¹,

Khaliq²,

Aslam³

et al. 2015

Bangladesh J Pharmacol

View full text Add to dashboard Cite

Peptic ulcer disease (PUD) is a main source of morbidity and mortality worldwide. It is characterized by erosions in mucosal linings of stomach and duodenum. Non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori are mainly responsible for peptic ulcer disease. Histamine receptor blockers and proton pump inhibitors are most prominent therapies in the treatment of peptic ulcer. However, severe adverse effects of NSAIDs have been reported. Therefore, focus is now diverted towards herbal formulations of medicinal plants for the treatment of ulcer. Plants contain different phytoconstituents which are responsible for increasing defensive mechanisms of body against peptic ulcer. The current review focuses on the commonly used gastroprotective plants as antiulcer agents.

show abstract

A meta‐analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

Abstract: Fourteen-day, proton pump inhibitor-based triple therapy achieves better results than 7-day schedules. Additional data are necessary to evaluate 10-day therapies.

Cited by 224 publications

References 29 publications

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

3rd BRAZILIAN CONSENSUS ON Helicobacter pylori

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Medicinal plants with gastroprotective potential

Contact Info

Product

Resources

About